investigated the viability of serum hepcidin in the quest to find a suitable biomarker to correlate patient’s survival in urinary tract urothelial carcinomas (UUTUC) and RCC as a potential biomarker in UUTUC and RCC (59). Here, HAMP is linked to renal cell carcinoma.